| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11007916 | Value in Health | 2018 | 11 Pages |
Abstract
For rPFS, the NMA suggests that enzalutamide is superior to abiraterone/prednisone and sipuleucel-T. There is no evidence of a statistically significant difference in OS between enzalutamide and abiraterone/prednisone, sipuleucel-T, or radium-223. Given the limitations in network construction and underlying assumptions made to complete these analyses, results should be interpreted with caution.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Rachael BSc, Kelly MSc, Julie MSc, Mick BA, MA, Howard MBChB, BSc, Shevani PharmD,